Benitec Biopharma Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 8.74 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 304.88M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene, which is in phase 1b/2a for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Details
| Name | Benitec Biopharma Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 24 |
| Founded | 1995 |
| Ceo | Jerel Banks |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| Isin | US08205P2092 |
| Cusip | 08205P209 |
| Cik | 0001808898 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Sophie Mukadam | Chief Operating Officer |
| Dr. Michael Graham | Head of Discovery and Founding Scientist |
| Dr. Claudia Kloth Ph.D. | Senior Vice President of Manufacturing |
Contact
| Address | 3940 Trust Way, Hayward, California 94545, United States |
| Phone | 510 780 0819 |
| Website | https://benitec.com |